New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
November 21, 2014
16:36 EDTINTCMarket ends week higher as domestic data, foreign central banks boost shares
Subscribe for More Information
13:31 EDTCOV, MDTCovidien announces mailing of definitive joint proxy statement, prospectus
Covidien (COV) announced, for purposes of the Irish Takeover Rules, that the definitive joint proxy statement of Covidien and Medtronic (MDT), which also serves as a prospectus of Medtronic Holdings Limited and comprises Covidienís scheme circular required under Irish law is being sent today to Covidien and Medtronic shareholders. As previously announced, on June 15, Covidien and Medtronic entered into a definitive agreement pursuant to which Medtronic Holdings Limited, a new holding company incorporated in Ireland that will be renamed Medtronic plc, will acquire Covidien and Medtronic. The joint proxy statement/prospectus will contain important information about the transaction for shareholders of both companies, as well as notices of the shareholder meetings and instructions on voting online, by mail, by telephone or in person.
10:00 EDTINTCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:06 EDTINTCIntel DCG growth could add 15c-20c to 2015 EPS, says Jefferies
Jefferies says the bear argument on Intel misses the fact that the company's Data Center Group is expected to growth 15% annually for the foreseeable future. The firm estimates DCG growth could add $1B in free cash flow and 15c-20c in EPS In 2015. If also estimates Intel's PC revenue, which the bears highlight, will increase by 4% in 2014 to $35B, at 45% operating margin and contribute $2.00 in EPS. Jefferies reiterates a Buy rating on Intel with a $45 price target.
07:56 EDTINTCIntel analyst day mixed, says FBR Capital
FBR Capital views Intel's analyst day as mixed since the company's gross margin and PC guidance came in below its expectations while it also announced a dividend increase and better than expected capex outlook. FBR raised its price target for Intel shares to $40 from $36 saying the cash return story is likely to temp income investors. It keeps an Outperform rating on the stock.
07:35 EDTINTC, INTCIntel downgraded to Sell from Underperform at CLSA
Price target is $31.
07:29 EDTINTCIntel data center unit forecast beat estimates, says Pacific Crest
Pacific Crest says that Intel's 2015 guidance for its data center unit surpassed consensus estimates. The firm notes that the unit generates 42% of the company's operating profits, and it thinks the company has a number of other positive catalysts. It recommends buying the shares.
06:05 EDTINTCIntel may not reach goal of shipping 70M tablet chips next year, Re/code reports
Intel CEO Bryan Krzanich said in an interview on the sidelines of the company's investor meeting that the company may not ship 70M tablet chips in 2015 as previously predicted, Re/code reports. Krzanich commented, "I donít think our standalone number will be that high." Reference Link
November 20, 2014
16:24 EDTINTCOn The Fly: Closing Wrap
Subscribe for More Information
13:59 EDTINTCIntel remains a top pick at Wells Fargo
Wells Fargo says Intel's outlook for 2015 is "roughly consistent" with its estimates. It expects Intel's competitive strength to profitability and share value over the next several years. The firm views Intel as a top pick and keeps an Outperform rating on the stock.
12:34 EDTINTCIntel sees FY15 R&D spending approximately $20B, plus or minus $400M
Subscribe for More Information
12:33 EDTINTCIntel sees FY15 CapEx approximately $10.5B, plus or minus $500M
Subscribe for More Information
12:32 EDTINTCIntel sees FY15 gross margin 62%, plus or minus two points
12:32 EDTINTCIntel sees FY15 revenue growth in mid-single digits, consensus $57.78B
12:31 EDTINTCIntel raises annual dividend to 96c per share
Subscribe for More Information
11:52 EDTINTCIntel CEO confirms organizational change made this week
The Wall Street Journal reported earlier this week that Intel has reorganized by combing its groups that handle personal computer chips with those used for smartphones and tablets, and Intel CEO Brian Krzanich confirmed the change during the company's investor day presentation.
11:32 EDTINTCIntel says high-end gaming segment among fastest growing in PCs
Subscribe for More Information
07:31 EDTBSXBoston Scientific should be bought on weakness, says RBC Capital
Subscribe for More Information
05:14 EDTCOVCovidien achieves CE Mark for Nellcor Bedside SpO2 Patient Monitoring System
Subscribe for More Information
November 19, 2014
13:42 EDTVRTXVertex peak CF sales have bullish read from Royalty Pharma bet, TheStreet says
Subscribe for More Information
12:11 EDTBSXBoston Scientific says Synergy stent met primary endpoint in trial
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. Additionally, favorable rates for key secondary endpoints were observed with the SYNERGY Stent. Dean Kereiakes, M.D., F.A.C.C., F.S.C.A.I., the principal investigator for the EVOLVE II Trial, presented the study results today in a Late Breaking Clinical Trial session at the American Heart Association Scientific Session 2014 in Chicago. Key findings for the SYNERGY Stent from the EVOLVE II Trial include the following: At 12 months, the TLF rate was 6.4% per protocol and 6.7% for intent-to-treat. Stent Thrombosis was rare, with Definite or Probable ST occurring in only 0.4% of patients through one year. No Definite ST occurred after 24 hours.
10:42 EDTVRTXUBS hosts a conference call with Vertex Pharmaceuticals
Subscribe for More Information
10:29 EDTINTCGoogle now top competitor to Apple, Jefferies says
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
08:15 EDTCOV, MDTMedtronic reported solid Q2 results, says Bernstein
Bernstein notes that Medtronic's (MDT) sales growth accelerated to 5%, and the firm thinks the company's market share of the ICD market is poised to increase next quarter. Bernstein views Medtronic as "a strong buy" into the close of its acquisition of Covidien (COV). The firm reiterates an Outperform rating on Medtronic.
07:52 EDTVRTXInforma Business Information to hold a conference
Subscribe for More Information
07:27 EDTVRTXRoyalty Pharma acquires royalties on Vertex Pharmaceuticals CF treatments
Subscribe for More Information
06:54 EDTCOV, MDTMedtronic reiterated as a top pick at JPMorgan
Subscribe for More Information
06:30 EDTBSX, JNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
12:08 EDTMDT, COVOn The Fly: Midday Wrap
Subscribe for More Information
11:50 EDTINTCIntel November volatility elevated into investor meeting
Subscribe for More Information
11:35 EDTBSXBoston Scientific November volatility elevated into investor day
Subscribe for More Information
10:55 EDTINTCIntel to host investor meeting
Investor meeting to be held in Santa Clara, CA on November 20 at 11 am. Webcast Link
09:08 EDTCOV, MDTMedtronic says regulatory processes for Covidien deal 'all on track'
Subscribe for More Information
09:06 EDTINTCIntel to combine two groups in new 'Client Computing' unit, WSJ says
Intel plans to reorganize by combing its groups that handle personal computer chips with those used for smartphones and tablets, according to The Wall Street Journal, citing an email sent to employees by CEO Brian Krzanich. Intelís changes are scheduled to go into effect in early 2015, the report noted. Reference Link
08:39 EDTMDTMedtronic says 'would not be surprised' to be at high end of FY15 guidance range
Subscribe for More Information
08:39 EDTMDTMedtronic sees 2H15 gross margin 74.5%
Subscribe for More Information
08:34 EDTMDTMedtronic sees Diabetes operations to have difficult comparison in Q3
Subscribe for More Information
08:28 EDTMDTMedtronic sees U.S. approval for IMPACT Admiral balloon in Q1
Subscribe for More Information
07:37 EDTBSXStifel to hold a conference
Subscribe for More Information
07:20 EDTMDT, COVMedtronic confirms commitment to Covidien transaction
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS $4.00-$4.10, consensus $4.05
Narrows FY15 revenue guidance to up 4%-5% from 3%-5%.
07:17 EDTMDTMedtronic reports Q2 EPS 96c, consensus 96c
Subscribe for More Information
06:08 EDTINTCIntel's 'Mica' bracelet to feature Google alerts, AT&T data plan, Re/code says
Subscribe for More Information
06:08 EDTBSXBoston Scientific to host investor meeting
Investor meeting to be held on November 19 at 2 pm. Webcast Link
November 17, 2014
15:16 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
09:08 EDTBSXBoston Scientific announces first U.S. procedures with Symphion completed
Subscribe for More Information
08:57 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 28, December is at 21, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
07:52 EDTINTCDepartment of Energy awards $425M for supercomputing technologies
Subscribe for More Information
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 16, 2014
14:08 EDTMDTDaVita announces collaboration with Medtronic
DaVita Kidney Care, a division of DaVita HealthCare Partners (DVA) and leading provider of kidney care services, announced a collaboration with Medtronic (MDT) to better understand cardiovascular health in end stage renal disease, ESRD patients. The collaboration will focus on developing a pilot program using Medtronic's Reveal LINQ Insertable Cardiac Monitoring system to identify cardiac arrhythmias in patients receiving dialysis. "Medtronic recently announced data at the American Society of Nephrology meeting that showed a higher incidence of arrhythmias in patients receiving hemodialysis," said Ven Manda, vice president, Renal Care Solutions at Medtronic. "We are pleased to pursue this collaboration with DaVita to monitor more patients and gather additional data that will further our understanding of the relationship between dialysis and cardiac events in ESRD patients." "Given the high incidence rate of cardiovascular disease and events in ESRD patients, we believe that by collaborating with Medtronic, we can gain knowledge to help improve the lives of ESRD patients," said Mahesh Krishnan, vice president for clinical innovation and public policy for DaVita HealthCare Partners. "Through the collaboration we expect to utilize innovative monitoring technology and data from our DaVita Kidney Care information systems across the country. This effort is poised to improve the lives of patients by proactively detecting and preventing cardiac complications."
November 14, 2014
17:27 EDTCOVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:53 EDTBSXOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
12:43 EDTCOV, MDTMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTCOV, MDTMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
November 13, 2014
18:07 EDTCOVCovidien' VenaSeal closure system shows positive results
Covidien announced the six-month results of the VeClose pivotal study of the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein. The VeClose randomized controlled non-inferiority study compared the safety and effectiveness of the VenaSeal system to that of the ClosureFast endovenous radiofrequency ablation catheter. Covidien's ClosureFast catheter is an endovenous radiofrequency ablation catheter designed to collapse and close enlarged leg veins. The VenaSeal system is not approved and currently limited to investigational use in the U.S. At three months, the complete closure of the great saphenous veins achieved in more than 98.9% of patients treated with the VenaSeal system compared to 95.6% of patients treated with the ClosureFast catheter. The closure rate at six months was 98.9% and 94.3%.
17:10 EDTBSXBoston Scientific S-ICD System receives favorable coding, payment designations
Subscribe for More Information
16:35 EDTMDTMedtronic study reveals heart rhythm disorders in patients with ESRD
Subscribe for More Information
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
14:50 EDTMDTLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTMDTLonestar capital to shut down, DJ reports
Subscribe for More Information
13:27 EDTCOV, MDTMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
November 12, 2014
15:08 EDTINTCEarnings Preview: Cisco reports amid analyst debate on break-up potential
Subscribe for More Information
14:08 EDTINTCIntel reports 427.7K share position in Rocket Fuel
Subscribe for More Information
07:27 EDTBSXNorth American Spine Society to hold annual meeting
Subscribe for More Information
07:23 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 23, December is at 20, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
November 11, 2014
07:24 EDTCOV, MDTMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
November 10, 2014
15:54 EDTCOVAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:10 EDTMDTMedtronic announces Japanese approval, launch of Evera MRI SureScan ICD
Subscribe for More Information
08:36 EDTCOVBSD Medical names Clint Carnell as president and CEO
Subscribe for More Information
07:44 EDTJNJJohnson & Johnson looks for acquisitions to help expand in China, WSJ says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use